Tumour progression and metastasis

被引:54
|
作者
Arvelo, Francisco [1 ,2 ]
Sojo, Felipe [1 ,2 ]
Cotte, Carlos [2 ]
机构
[1] Fdn Inst Estudios Avanzado IDEA, Ctr Biociencias, Apartado 17606, Caracas 1015A, Venezuela
[2] Cent Univ Venezuela, Inst Biol Expt, Lab Cult Tejidos & Biol Tumores, Apartado 47114, Caracas 1041A, Venezuela
来源
ECANCERMEDICALSCIENCE | 2016年 / 10卷
关键词
cancer; infiltration; metastasis; microenvironment; metastatic niche; latency; epithelial-mesenchymal transition;
D O I
10.3332/ecancer.2016.617
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The two biological mechanisms that determine types of malignancy are infiltration and metastasis, for which tumour microenvironment plays a key role in developing and establishing the morphology, growth and invasiveness of a malignancy. The microenvironment is formed by complex tissue containing the extracellular matrix, tumour and non-tumour cells, a signalling network of cytokines, chemokines, growth factors, and proteases that control autocrine and paracrine communication among individual cells, facilitating tumour progression. During the development of the primary tumour, the tumour stroma and continuous genetic changes within the cells makes it possible for them to migrate, having to count on a pre-metastatic niche receptor that allows the tumour's survival and distant growth. These niches are induced by factors produced by the primary tumour; if it is eradicated, the active niches become responsible for activating the latent disseminated cells. Due to the importance of these mechanisms, the strategies that develop tumour cells during tumour progression and the way in which the microenvironment influences the formation of metastasis are reviewed. It also suggests that the metastatic niche can be an ideal target for new treatments that make controlling metastasis possible.
引用
收藏
页数:25
相关论文
共 50 条
  • [41] Metabolic Constrains Rule Metastasis Progression
    Roda, Niccolo'
    Gambino, Valentina
    Giorgio, Marco
    CELLS, 2020, 9 (09) : 1 - 32
  • [42] Metastasis: an early event in cancer progression
    Yijun Hu
    Xiya Yu
    Guixia Xu
    Shanrong Liu
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 745 - 757
  • [43] Ezrin gone rogue in cancer progression and metastasis: An enticing therapeutic target
    Barik, Ganesh Kumar
    Sahay, Osheen
    Paul, Debasish
    Santra, Manas Kumar
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (04):
  • [44] Oesophageal adenocarcinoma metastasis into a microcystic meningioma: a rare occurrence of tumour to tumour metastasis
    Khan, Basil Zia
    Akinjise-Ferdinand, Oluwaseun
    Kumar, Bhaskar
    BJR CASE REPORTS, 2022, 8 (02):
  • [45] SIGNIFICANCE OF TALIN IN CANCER PROGRESSION AND METASTASIS
    Desiniotis, Andreas
    Kyprianou, Natasha
    INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 289, 2011, 289 : 117 - 147
  • [46] The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression
    Junli Deng
    Li Wang
    Hongmin Chen
    Lei Li
    Yiming Ma
    Jie Ni
    Yong Li
    Cancer and Metastasis Reviews, 2013, 32 : 535 - 551
  • [47] The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression
    Deng, Junli
    Wang, Li
    Chen, Hongmin
    Li, Lei
    Ma, Yiming
    Ni, Jie
    Li, Yong
    CANCER AND METASTASIS REVIEWS, 2013, 32 (3-4) : 535 - 551
  • [48] A pituitary metastasis, an adenoma and potential hypophysitis: A case report of tumour to tumour metastasis in the pituitary
    Castle-Kirszbaum, Mendel
    Teik Beng Phung
    Luen, Stephen J.
    Rimmer, Joanne
    Chandra, Ronil V.
    Goldschlager, Tony
    JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 81 : 161 - 166
  • [49] Involvement of redox signalling in tumour cell dormancy and metastasis
    Puente-Cobacho, Beatriz
    Varela-Lopez, Alfonso
    Quiles, Jose L.
    Vera-Ramirez, Laura
    CANCER AND METASTASIS REVIEWS, 2023, 42 (01) : 49 - 85
  • [50] ROS and TGFβ: from pancreatic tumour growth to metastasis
    Chang, Chao-Hui
    Pauklin, Siim
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)